APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Stromal Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastrointestinal Stromal Tumor Drug Market Outlook and Growth Opportunities 2026

29 December 2025215 pages

Choose your research edition.

Industry ResearchGastrointestinal Stromal Tumor Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Stromal Tumor Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Stromal Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Stromal Tumor Drug Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Stromal Tumor Drug Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Gastrointestinal Stromal Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Stromal Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastrointestinal Stromal Tumor Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastrointestinal Stromal Tumor Drug market include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastrointestinal Stromal Tumor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastrointestinal Stromal Tumor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastrointestinal Stromal Tumor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastrointestinal Stromal Tumor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastrointestinal Stromal Tumor Drug Segment by Company

China Biopharmaceuticals

Zai Lab

CSPC Pharmaceuticals

Novartis

Mylan Pharms Inc.

Kelun Pharmaceuticals

CStone Pharmaceuticals

Hansoh Pharmaceuticals

Vannsh Life Sciences

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceuticals

MSN Laboratories

Glenmark Pharmaceuticals Ltd.

Drug International

Dr. Reddy's Laboratories

Deciphera Pharmaceuticals

Bulat Pharmaceutical

Beacon Pharmaceuticals

Bayer Pharmaceuticals

Apotex Inc.

Actavis Generics

Gastrointestinal Stromal Tumor Drug Segment by Type

Ripretinib

Regorafenib

Sunitinib

Imatinib

Others

Gastrointestinal Stromal Tumor Drug Segment by Application

Hospital

Clinic

Others

Gastrointestinal Stromal Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastrointestinal Stromal Tumor Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastrointestinal Stromal Tumor Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastrointestinal Stromal Tumor Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Gastrointestinal Stromal Tumor Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastrointestinal Stromal Tumor Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastrointestinal Stromal Tumor Drug industry.

Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastrointestinal Stromal Tumor Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastrointestinal Stromal Tumor Drug Industry Trends Table 2. Gastrointestinal Stromal Tumor Drug Industry Drivers Table 3. Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges Table 4. Gastrointestinal Stromal Tumor Drug Industry Restraints Table 5. Global Gastrointestinal Stromal Tumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastrointestinal Stromal Tumor Drug Revenue Share by Company (2021-2026) Table 7. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Company (2021-2026) Table 9. Global Gastrointestinal Stromal Tumor Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Gastrointestinal Stromal Tumor Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastrointestinal Stromal Tumor Drug Key Company Manufacturing Base & Headquarters Table 12. Global Gastrointestinal Stromal Tumor Drug Company, Product Type & Application Table 13. Global Gastrointestinal Stromal Tumor Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastrointestinal Stromal Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ripretinib Table 18. Significant Companies of Regorafenib Table 19. Significant Companies of Sunitinib Table 20. Significant Companies of Imatinib Table 21. Significant Companies of Others Table 22. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Type (2021-2026) Table 26. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Type (2027-2032) Table 27. Global Gastrointestinal Stromal Tumor Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Gastrointestinal Stromal Tumor Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Gastrointestinal Stromal Tumor Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Type (2021-2026) Table 31. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Application (2021-2026) Table 39. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Application (2027-2032) Table 40. Global Gastrointestinal Stromal Tumor Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Gastrointestinal Stromal Tumor Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Gastrointestinal Stromal Tumor Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Application (2021-2026) Table 44. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Application (2027-2032) Table 45. Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2021-2026) Table 48. Global Gastrointestinal Stromal Tumor Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region (2027-2032) Table 50. Global Gastrointestinal Stromal Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Gastrointestinal Stromal Tumor Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Region (2021-2026) Table 53. Global Gastrointestinal Stromal Tumor Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Region (2027-2032) Table 55. Global Gastrointestinal Stromal Tumor Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Gastrointestinal Stromal Tumor Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Gastrointestinal Stromal Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2021-2026) Table 61. Global Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Country (2027-2032) Table 63. Global Gastrointestinal Stromal Tumor Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Gastrointestinal Stromal Tumor Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Gastrointestinal Stromal Tumor Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Gastrointestinal Stromal Tumor Drug Sales Value Market Share by Country (2027-2032) Table 67. China Biopharmaceuticals Company Information Table 68. China Biopharmaceuticals Business Overview Table 69. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 71. China Biopharmaceuticals Recent Development Table 72. Zai Lab Company Information Table 73. Zai Lab Business Overview Table 74. Zai Lab Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio Table 76. Zai Lab Recent Development Table 77. CSPC Pharmaceuticals Company Information Table 78. CSPC Pharmaceuticals Business Overview Table 79. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 81. CSPC Pharmaceuticals Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio Table 86. Novartis Recent Development Table 87. Mylan Pharms Inc. Company Information Table 88. Mylan Pharms Inc. Business Overview Table 89. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 91. Mylan Pharms Inc. Recent Development Table 92. Kelun Pharmaceuticals Company Information Table 93. Kelun Pharmaceuticals Business Overview Table 94. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 96. Kelun Pharmaceuticals Recent Development Table 97. CStone Pharmaceuticals Company Information Table 98. CStone Pharmaceuticals Business Overview Table 99. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 101. CStone Pharmaceuticals Recent Development Table 102. Hansoh Pharmaceuticals Company Information Table 103. Hansoh Pharmaceuticals Business Overview Table 104. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 106. Hansoh Pharmaceuticals Recent Development Table 107. Vannsh Life Sciences Company Information Table 108. Vannsh Life Sciences Business Overview Table 109. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio Table 111. Vannsh Life Sciences Recent Development Table 112. Teva Pharmaceutical Industries Ltd. Company Information Table 113. Teva Pharmaceutical Industries Ltd. Business Overview Table 114. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 116. Teva Pharmaceutical Industries Ltd. Recent Development Table 117. Sun Pharmaceuticals Company Information Table 118. Sun Pharmaceuticals Business Overview Table 119. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 121. Sun Pharmaceuticals Recent Development Table 122. MSN Laboratories Company Information Table 123. MSN Laboratories Business Overview Table 124. MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 126. MSN Laboratories Recent Development Table 127. Glenmark Pharmaceuticals Ltd. Company Information Table 128. Glenmark Pharmaceuticals Ltd. Business Overview Table 129. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 131. Glenmark Pharmaceuticals Ltd. Recent Development Table 132. Drug International Company Information Table 133. Drug International Business Overview Table 134. Drug International Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio Table 136. Drug International Recent Development Table 137. Dr. Reddy's Laboratories Company Information Table 138. Dr. Reddy's Laboratories Business Overview Table 139. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio Table 141. Dr. Reddy's Laboratories Recent Development Table 142. Deciphera Pharmaceuticals Company Information Table 143. Deciphera Pharmaceuticals Business Overview Table 144. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 146. Deciphera Pharmaceuticals Recent Development Table 147. Bulat Pharmaceutical Company Information Table 148. Bulat Pharmaceutical Business Overview Table 149. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio Table 151. Bulat Pharmaceutical Recent Development Table 152. Beacon Pharmaceuticals Company Information Table 153. Beacon Pharmaceuticals Business Overview Table 154. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 156. Beacon Pharmaceuticals Recent Development Table 157. Bayer Pharmaceuticals Company Information Table 158. Bayer Pharmaceuticals Business Overview Table 159. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio Table 161. Bayer Pharmaceuticals Recent Development Table 162. Apotex Inc. Company Information Table 163. Apotex Inc. Business Overview Table 164. Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio Table 166. Apotex Inc. Recent Development Table 167. Actavis Generics Company Information Table 168. Actavis Generics Business Overview Table 169. Actavis Generics Gastrointestinal Stromal Tumor Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio Table 171. Actavis Generics Recent Development Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Gastrointestinal Stromal Tumor Drug Distributors List Table 175. Gastrointestinal Stromal Tumor Drug Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. Gastrointestinal Stromal Tumor Drug Product Image Figure 2. Global Gastrointestinal Stromal Tumor Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastrointestinal Stromal Tumor Drug Sales (2021-2032) & (K Units) Figure 5. Global Gastrointestinal Stromal Tumor Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Gastrointestinal Stromal Tumor Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ripretinib Image Figure 10. Regorafenib Image Figure 11. Sunitinib Image Figure 12. Imatinib Image Figure 13. Others Image Figure 14. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Gastrointestinal Stromal Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastrointestinal Stromal Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Gastrointestinal Stromal Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Gastrointestinal Stromal Tumor Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Application (2021-2032) Figure 29. Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Gastrointestinal Stromal Tumor Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Gastrointestinal Stromal Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Gastrointestinal Stromal Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Gastrointestinal Stromal Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Gastrointestinal Stromal Tumor Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Gastrointestinal Stromal Tumor Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Gastrointestinal Stromal Tumor Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Ripretinib
  • Regorafenib
  • Sunitinib
  • Imatinib
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • China Biopharmaceuticals
  • Zai Lab
  • CSPC Pharmaceuticals
  • Novartis
  • Mylan Pharms Inc.
  • Kelun Pharmaceuticals
  • CStone Pharmaceuticals
  • Hansoh Pharmaceuticals
  • Vannsh Life Sciences
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceuticals
  • MSN Laboratories
  • Glenmark Pharmaceuticals Ltd.
  • Drug International
  • Dr. Reddy's Laboratories
  • Deciphera Pharmaceuticals
  • Bulat Pharmaceutical
  • Beacon Pharmaceuticals
  • Bayer Pharmaceuticals
  • Apotex Inc.
  • Actavis Generics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032)
  4. 1.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastrointestinal Stromal Tumor Drug Market Dynamics
  1. 2.1 Gastrointestinal Stromal Tumor Drug Industry Trends
  2. 2.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
  3. 2.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
3 Gastrointestinal Stromal Tumor Drug Market by Company
  1. 3.1 Global Gastrointestinal Stromal Tumor Drug Company Revenue Ranking in 2025
  2. 3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Company (2021-2026)
  3. 3.3 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastrointestinal Stromal Tumor Drug Average Price by Company (2021-2026)
  5. 3.5 Global Gastrointestinal Stromal Tumor Drug Company Ranking (2024-2026)
  6. 3.6 Global Gastrointestinal Stromal Tumor Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastrointestinal Stromal Tumor Drug Company Product Type and Application
  8. 3.8 Global Gastrointestinal Stromal Tumor Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastrointestinal Stromal Tumor Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastrointestinal Stromal Tumor Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastrointestinal Stromal Tumor Drug Market by Type
  1. 4.1 Gastrointestinal Stromal Tumor Drug Type Introduction
  2. 4.1.1 Ripretinib
  3. 4.1.2 Regorafenib
  4. 4.1.3 Sunitinib
  5. 4.1.4 Imatinib
  6. 4.1.5 Others
  7. 4.2 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type
  8. 4.2.1 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Gastrointestinal Stromal Tumor Drug Sales Value by Type
  12. 4.3.1 Global Gastrointestinal Stromal Tumor Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gastrointestinal Stromal Tumor Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Type (2021-2032)
5 Gastrointestinal Stromal Tumor Drug Market by Application
  1. 5.1 Gastrointestinal Stromal Tumor Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application
  6. 5.2.1 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Gastrointestinal Stromal Tumor Drug Sales Value by Application
  10. 5.3.1 Global Gastrointestinal Stromal Tumor Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gastrointestinal Stromal Tumor Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Gastrointestinal Stromal Tumor Drug Sales Value Share by Application (2021-2032)
6 Gastrointestinal Stromal Tumor Drug Regional Sales and Value Analysis
  1. 6.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2027-2032)
  5. 6.3 Global Gastrointestinal Stromal Tumor Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastrointestinal Stromal Tumor Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastrointestinal Stromal Tumor Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastrointestinal Stromal Tumor Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Gastrointestinal Stromal Tumor Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032)
  12. 6.6.2 North America Gastrointestinal Stromal Tumor Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Gastrointestinal Stromal Tumor Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032)
  21. 6.9.2 South America Gastrointestinal Stromal Tumor Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastrointestinal Stromal Tumor Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastrointestinal Stromal Tumor Drug Sales Value Share by Country, 2025 VS 2032
7 Gastrointestinal Stromal Tumor Drug Country-level Sales and Value Analysis
  1. 7.1 Global Gastrointestinal Stromal Tumor Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastrointestinal Stromal Tumor Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Gastrointestinal Stromal Tumor Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Gastrointestinal Stromal Tumor Drug Sales by Country (2027-2032)
  6. 7.4 Global Gastrointestinal Stromal Tumor Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastrointestinal Stromal Tumor Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastrointestinal Stromal Tumor Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastrointestinal Stromal Tumor Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastrointestinal Stromal Tumor Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastrointestinal Stromal Tumor Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Biopharmaceuticals
  2. 8.1.1 China Biopharmaceuticals Company Information
  3. 8.1.2 China Biopharmaceuticals Business Overview
  4. 8.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  6. 8.1.5 China Biopharmaceuticals Recent Developments
  7. 8.2 Zai Lab
  8. 8.2.1 Zai Lab Company Information
  9. 8.2.2 Zai Lab Business Overview
  10. 8.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
  12. 8.2.5 Zai Lab Recent Developments
  13. 8.3 CSPC Pharmaceuticals
  14. 8.3.1 CSPC Pharmaceuticals Company Information
  15. 8.3.2 CSPC Pharmaceuticals Business Overview
  16. 8.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  18. 8.3.5 CSPC Pharmaceuticals Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Mylan Pharms Inc.
  26. 8.5.1 Mylan Pharms Inc. Company Information
  27. 8.5.2 Mylan Pharms Inc. Business Overview
  28. 8.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  30. 8.5.5 Mylan Pharms Inc. Recent Developments
  31. 8.6 Kelun Pharmaceuticals
  32. 8.6.1 Kelun Pharmaceuticals Company Information
  33. 8.6.2 Kelun Pharmaceuticals Business Overview
  34. 8.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  36. 8.6.5 Kelun Pharmaceuticals Recent Developments
  37. 8.7 CStone Pharmaceuticals
  38. 8.7.1 CStone Pharmaceuticals Company Information
  39. 8.7.2 CStone Pharmaceuticals Business Overview
  40. 8.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  42. 8.7.5 CStone Pharmaceuticals Recent Developments
  43. 8.8 Hansoh Pharmaceuticals
  44. 8.8.1 Hansoh Pharmaceuticals Company Information
  45. 8.8.2 Hansoh Pharmaceuticals Business Overview
  46. 8.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  48. 8.8.5 Hansoh Pharmaceuticals Recent Developments
  49. 8.9 Vannsh Life Sciences
  50. 8.9.1 Vannsh Life Sciences Company Information
  51. 8.9.2 Vannsh Life Sciences Business Overview
  52. 8.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
  54. 8.9.5 Vannsh Life Sciences Recent Developments
  55. 8.10 Teva Pharmaceutical Industries Ltd.
  56. 8.10.1 Teva Pharmaceutical Industries Ltd. Company Information
  57. 8.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
  58. 8.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  61. 8.11 Sun Pharmaceuticals
  62. 8.11.1 Sun Pharmaceuticals Company Information
  63. 8.11.2 Sun Pharmaceuticals Business Overview
  64. 8.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  66. 8.11.5 Sun Pharmaceuticals Recent Developments
  67. 8.12 MSN Laboratories
  68. 8.12.1 MSN Laboratories Company Information
  69. 8.12.2 MSN Laboratories Business Overview
  70. 8.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  72. 8.12.5 MSN Laboratories Recent Developments
  73. 8.13 Glenmark Pharmaceuticals Ltd.
  74. 8.13.1 Glenmark Pharmaceuticals Ltd. Company Information
  75. 8.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
  76. 8.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
  78. 8.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  79. 8.14 Drug International
  80. 8.14.1 Drug International Company Information
  81. 8.14.2 Drug International Business Overview
  82. 8.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
  84. 8.14.5 Drug International Recent Developments
  85. 8.15 Dr. Reddy's Laboratories
  86. 8.15.1 Dr. Reddy's Laboratories Company Information
  87. 8.15.2 Dr. Reddy's Laboratories Business Overview
  88. 8.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
  90. 8.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 8.16 Deciphera Pharmaceuticals
  92. 8.16.1 Deciphera Pharmaceuticals Company Information
  93. 8.16.2 Deciphera Pharmaceuticals Business Overview
  94. 8.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  96. 8.16.5 Deciphera Pharmaceuticals Recent Developments
  97. 8.17 Bulat Pharmaceutical
  98. 8.17.1 Bulat Pharmaceutical Company Information
  99. 8.17.2 Bulat Pharmaceutical Business Overview
  100. 8.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
  102. 8.17.5 Bulat Pharmaceutical Recent Developments
  103. 8.18 Beacon Pharmaceuticals
  104. 8.18.1 Beacon Pharmaceuticals Company Information
  105. 8.18.2 Beacon Pharmaceuticals Business Overview
  106. 8.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  108. 8.18.5 Beacon Pharmaceuticals Recent Developments
  109. 8.19 Bayer Pharmaceuticals
  110. 8.19.1 Bayer Pharmaceuticals Company Information
  111. 8.19.2 Bayer Pharmaceuticals Business Overview
  112. 8.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
  114. 8.19.5 Bayer Pharmaceuticals Recent Developments
  115. 8.20 Apotex Inc.
  116. 8.20.1 Apotex Inc. Company Information
  117. 8.20.2 Apotex Inc. Business Overview
  118. 8.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
  120. 8.20.5 Apotex Inc. Recent Developments
  121. 8.21 Actavis Generics
  122. 8.21.1 Actavis Generics Company Information
  123. 8.21.2 Actavis Generics Business Overview
  124. 8.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
  126. 8.21.5 Actavis Generics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
  2. 9.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastrointestinal Stromal Tumor Drug Sales Mode & Process
  6. 9.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastrointestinal Stromal Tumor Drug Distributors
  9. 9.2.3 Gastrointestinal Stromal Tumor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst